Skip to main content
. 2022 Nov 19;22:470. doi: 10.1186/s12876-022-02580-8

Table 6.

Incidence of adverse events after treatment in the two groups

Group Chi-square test (P value)
PSE + Hep + DEX group (N = 54) PSE group (N = 62)
Abdominal pain No Count (%) 29 (53.7%) 21 (33.9%) 0.039
Yes Count (%) 25 (46.3%) 41 (66.1%)
Fever No Count (%) 33 (61.1%) 15 (24.2%) 0.000
Yes Count (%) 21 (38.9%) 47 (75.8%)
Vomiting No Count (%) 46 (85.2%) 47 (75.8%) 0.248
Yes Count (%) 8 (14.8%) 15 (24.2%)
Hydrothorax No Count (%) 45 (83.3%) 43 (69.4%) 0.079
Yes Count (%) 9 (16.7%) 19 (30.6%)
Ascites No Count (%) 41 (75.9%) 38 (61.3%) 0.092
Yes Count (%) 13 (24.1%) 24 (38.7%)
Portal vein thrombosis No Count (%) 53 (98.1%) 54 (87.1%) 0.026
Yes Count (%) 1 (1.9%) 8 (12.9%)
Splenic abscess No Count (%) 54 (100.0%) 61 (98.4%) 0.349
Yes Count (%) 0 (0.0%) 1 (1.6%)
Refractory ascites No Count (%) 51 (94.4%) 50 (80.6%) 0.027
Yes Count (%) 3 (5.6%) 12 (19.4%)